E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hypotension after trauma, due to haemorrhage |
|
E.1.1.1 | Medical condition in easily understood language |
Very low blood pressure as a result of rapid bleeding due to injuries |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Injuries, poisonings, and occupational diseases [C21] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10053476 |
E.1.2 | Term | Traumatic haemorrhage |
E.1.2 | System Organ Class | 10022117 - Injury, poisoning and procedural complications |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Compared to the current standard of care, does resuscitation with blood products improve the quality of resuscitation (measured by venous lactate clearance during the first two hours from randomisation and reduce mortality in trauma patients? |
|
E.2.2 | Secondary objectives of the trial |
a. Compared to standard care, does pre-hospital blood product resuscitation: i. improve blood pressure, heart rate and capillary oxygenation on ED arrival? ii. prolong on-scene time? iii. reduce pre-hospital fluid requirements? iv. reduce in-hospital transfusion requirements? v. reduce trauma-induced coagulopathy? vi. preserve platelet function? vii.reduce deaths within three hours of hospital arrival viii.lead to a greater incidence of transfusion-related complications, particularly acute respiratory distress syndrome? ix.lead to blood product wastage?
b. Are outcomes influenced by: i. blunt vs. penetrating injury mechanism? ii. destination? iii. transport mode? iv. lactate on ED arrival? v. ED arrival within one hour of injury? vi. total pre-hospital fluid volume? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria: a. Traumatic injury b. Pre-Hospital Emergency Medical team attend c. Hypotension (SBP <90mmHg or absence of palpable radial pulse) believed to be due to traumatic haemorrhage.
|
|
E.4 | Principal exclusion criteria |
a. Children (known or apparently aged <16 years) b. Refusal of blood product administration; known Jehovah’s Witness c. Pregnancy (known or apparent) d. Isolated head injury
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is a composite consisting of episode mortality (from point of recruitment to discharge from initial hospital admission or death) and lactate clearance <20%/hr in the first two hours from randomisation. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Components: 1) Initial lactate clearance: 2h after admission to the Emergency Department (ED) 2) Episode mortality: at time of death or discharge from initial hospital admission |
|
E.5.2 | Secondary end point(s) |
1) individual components of primary outcome 2) pre-hospital time 3) pre-hospital fluid type and volume 4) on Emergency Department arrival: a) vital signs (systolic blood pressure, heart rate, capillary oxygen saturation) b) venous lactate concentration c) coagulation (measured viscoelastically with rotational thromboelastometery) d) coagulation (INR) e) platelet function (MultiPlate) 5) total blood product receipt at specified time points 6) during initial admission, incidence of: a) acute respiratory distress syndrome b) transfusion-related complications c) organ failure-free days d) mortality at 6 & 24 hours, 7 days and initial hospital admission 7) pre-hospital blood product wastage |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) As per B1-23-1 2) ED arrival 3) ED arrival 4) (all) ED arrival 4) d) also at 2 and 6 hours after ED arrival 5) 2, 6, 12 and 24 hours from ED arrival 6) (all) at time of death or discharge from initial hospital admission 7) Conclusion of study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Researchers and participants blinded to allocation until after recruitment into trial |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For the recruited participants their participation ends at death, hospital discharge or at 30 days follow‐up, whichever occurs first. The end of trial will be 30 days after the last data capture. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 30 |